BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181207
DTSTAMP:20260515T001418
CREATED:20180808T120122Z
LAST-MODIFIED:20180808T120525Z
UID:17076-1543881600-1544140799@www.pharmajournalist.com
SUMMARY:4th Annual Oncolytic Virotherapy Summit
DESCRIPTION:The 4th Oncolytic Virotherapy Summit is dedicated to improving the commercial success of oncolytic viruses\, in stand-alone and combination therapies. \n\nAs many oncolytic viruses progress through the clinical pipelines\, drug developers need to ensure that their therapies are safe\, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit\, where you will have an opportunity to pick the brains of 100+ senior industry peers and tackle your challenges in discovery\, clinical development\, manufacturing and regulations of oncolytic virotherapy. \nThis year we will be incorporating commercial insights from companies such as Merck\, Virogen\, Sagetis\, Lokon Pharma\, Replimmune\, Western Oncolytics\, DNAtrix and many more\, which will allow you to learn from their case studies and improve your development strategies. Participate in the interactive roundtable and workshops to build strategies that maximise success in the clinic and commercially. \nSounds interesting? Find out more – get free event brochure here: http://bit.ly/2KzCLIh
URL:https://www.pharmajournalist.com/event/4th-annual-oncolytic-virotherapy-summit/
LOCATION:Hilton Boston Back Bay Hotel\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:maggie.pang@oncolyticvirotherapies.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181206
DTSTAMP:20260515T001418
CREATED:20180821T073305Z
LAST-MODIFIED:20180821T073427Z
UID:17294-1543881600-1544054399@www.pharmajournalist.com
SUMMARY:Skin Microbiome Asia
DESCRIPTION:Skin Microbiome Asia | 4-5 December 2018 | Hong Kong – As K-Beauty and J-Beauty continue to storm the world\, beauty start-ups are also emerging from Australia\, India and across Southeast Asia.  China\, Singapore and Hong Kong remain mecca markets for international companies launching products into the region. There has never been a better time for cosmetics professionals to meet in Asia. \n \n150+ industry experts will be gathering in Hong Kong this December to learn about the science behind the products from companies like Unilever\, Cosmax\, Mother Dirt and more. \nJoin multinationals\, independent beauty brands\, sequencing companies\, regulators\, pharma & biotech companies and academia to build your network throughout Asia Pacific. \nInterested to learn more? Take a look at our agenda here: http://bit.ly/SkinAsiaAgenda \nOr take advantage of our Super Early Bird Pricing and book your pass here: http://bit.ly/SkinAsiaRegistration \nPraise for the event: \n“An incredible event… Fast paced and full of new and relevant information from a variety of perspectives\, each of which provide a complete and extensive snapshot of the industry and the future of microbiome friendly products”  – TrūAura Beauty \n“The value of this conference was absolutely unparalleled! I not only saw many old friends\, collaborators and partners\, but also met many new ones as well.”  – ProdermIQ \nTo learn more about Skin Microbiome Asia\, and to register online\, visit www.skinmicrobiomecongressasia.com
URL:https://www.pharmajournalist.com/event/skin-microbiome-asia/
LOCATION:Hong Kong\, Venue TBC
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181207
DTSTAMP:20260515T001418
CREATED:20180926T144030Z
LAST-MODIFIED:20180926T144030Z
UID:17791-1543881600-1544140799@www.pharmajournalist.com
SUMMARY:CBI’s Clinical Trial Agreement Series
DESCRIPTION:Designed to maximize your time out of the office\, CBI’s three-day Clinical Trial Agreement conference series allows your team to select the content that best meets your business objectives. Attend your preferred event or BOTH for maximum value\, learning and benchmarking. The Clinical Trial Legal and Contracting Forum\, taking place December 4-5 in Philadelphia\, serves as the only meeting that is singularly focused on the detailed legal and contracting issues that relate to clinical agreements of all types. The Clinical Trial Financial Management summit\, taking place December 5-6 in Philadelphia\, is designed to arm sponsors\, CROs\, AMCs and sites with the insights they need to develop\, negotiated and manage the financial aspects of clinical trial agreements. \nTo learn more about this event\, visit www.cbinet.com/ctafinance
URL:https://www.pharmajournalist.com/event/cbis-clinical-trial-agreement-series/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="CBI%2C a division of UBM Americas":MAILTO:cbireg@cbinet.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181206
DTSTAMP:20260515T001419
CREATED:20181010T095555Z
LAST-MODIFIED:20181010T095555Z
UID:17959-1543881600-1544054399@www.pharmajournalist.com
SUMMARY:BioFIT
DESCRIPTION:EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT  \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovations in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \nWHY ATTEND BIOFIT? \nOut of 1\,000 BioFIT attendees\, 1\,000 deals have been generated. The breakdown in terms of nature of deals is the following: \n\n35% of collaborative research projects\n30% of licensing deals\n15% of equity investment deals\n20% of services deals\n\nEstimate based on the measurement of 2015 and 2016 delegates’ outcomes \nKEY FIGURES: \n\n1\,200+ delegates\n800+ organisations\n35+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings (partneringONE platform from EBD Group)\nIdentification of would-be CEOs\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nWebsite: www.biofit-event.com\nTwitter: @BIOFIT_EVENT \nContact:\nMargaux Satola\nBusiness Development Manager\nmsatola@eurasante.com\n+33 (0)3 59 39 01 82
URL:https://www.pharmajournalist.com/event/biofit/
LOCATION:Lille Grand Palais  1 boulevard des Cités Unies  59000 Lille\, FRANCE\, France
ORGANIZER;CN="Eurasant%C3%A9%2C NHL Cluster%2C Alsace BioValley":MAILTO:biofit@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181206
DTEND;VALUE=DATE:20181208
DTSTAMP:20260515T001419
CREATED:20180503T162044Z
LAST-MODIFIED:20180530T113851Z
UID:15611-1544054400-1544227199@www.pharmajournalist.com
SUMMARY:The Digital Pathology Congress
DESCRIPTION:The congress will have expanded coverage of new areas such as AI and computational pathology alongside the latest case studies and applications. To complement the latest scientific presentations\, the conference will comprise of a vibrant exhibition room full of technology providers showcasing their technologies and other solutions; networking breaks allowing interaction with your peers; poster presentation sessions; and incisive Q&A panel discussions. Whether looking to hear more about the adoption and integration of digital pathology; seeking collaborations and tools to increase workflow; or uncover the latest developments in automated image analysis; the Congress is one not to be missed! \nTo learn more about this event\, and to register online\, visit https://goo.gl/42HTeh
URL:https://www.pharmajournalist.com/event/the-digital-pathology-congress/
LOCATION:London Heathrow Marriott Hotel\, London\, UK
ORGANIZER;CN="Global Engage":MAILTO:anna@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181210
DTEND;VALUE=DATE:20181212
DTSTAMP:20260515T001419
CREATED:20180613T100920Z
LAST-MODIFIED:20180613T101345Z
UID:16240-1544400000-1544572799@www.pharmajournalist.com
SUMMARY:Cold Chain Distribution
DESCRIPTION:SMi proudly presents the 13th annual Cold Chain Distribution Conference and Exhibition\, taking place at the Copthorne Tara Hotel in Kensington\, London between the 10th – 11th December. \n\nThe 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies\, from biotech’s to pharma\, need to adapt\, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry. \nThe two-day event will also look at various developments within the industry\, guiding companies on how best to ensure costs are kept low\, and quality remains high\, whilst simultaneously staying compliant to global regulations. \nThis year’s event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution. \nChairs for 2018: \n\nBob Hayes\, Director\, SeerPharma (UK)\nTony Wright\, CEO\, Exelsius\n\nFeatured Speakers: \n\nBob Hayes\, Director\, SeerPharma (UK)\nStephen Mitchell\, Quality Lead Logistics Partnerships\, GSK\nGianneOlaes-Dénis\, Supply Chain Quality Manager\, SanofiGenzymeEurope\nStefan Braun\, Managing Director\, SmartCAE\nGianpieroLorusso\, Director\, Supply Operations and GS\, Merck\nFrancicso Rizzuto\, Cargo Specialist\, Manager for Europe\, IATA\nMarco Gaudesi\, Pharmacist – GDP and Cold Chain Referent\, MSF\nHenk Mulder\, Head\, Digital Cargo\, IATA\n\nKey Highlights this December: \n\nEvaluate the current GDP guidelines\, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice\nExplore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved\nDiscover the temperature-controlled logistic solutions to best optimize your supply chain\nDiscuss the technical agreements within the supply chain and find out what questions you should be asking\nIdentify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process\n\nView the full agenda online: www.coldchain-distribution.com/pj \nEARLY-BIRD RATES: \n\nBOOK BY 29TH JUNE AND SAVE £400\nBOOK BY 28TH SEPTEMBER AND SAVE £300\nBOOK BY 31ST OCTOBER AND SAVE £100\n\nTo learn more about SMi’s Cold Chain Distribution\, and to register online\, visit www.coldchain-distribution.com/pj
URL:https://www.pharmajournalist.com/event/cold-chain-distribution/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:psolanki@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181210
DTEND;VALUE=DATE:20181213
DTSTAMP:20260515T001419
CREATED:20181016T110516Z
LAST-MODIFIED:20181016T110516Z
UID:18021-1544400000-1544659199@www.pharmajournalist.com
SUMMARY:Antigen-Specific Immune Tolerance Europe Summit
DESCRIPTION:Optimizing the Discovery\, Translation and Clinical Development of Safe and Effective Antigen-Specific Immune Tolerance Inducing Therapies to Treat Autoimmune Diseases. \n \nThe clinical heterogeneity of more than 80 autoimmune diseases presents a significant challenge with respect to the development of therapies designed to re-establish self-tolerance. As the first generation of antigen-specific immune tolerance therapies enters the clinic and excitement around the recent deals\, partnerships\, IPOs and investments reaching new heights\, now is the time for an industry forum for large pharma\, pioneering biotech and academia to unite. \nTackling key R&D challenges\, such as antigen identification\, animal model predictability\, translation and clinical design\, the Antigen-Specific Immune Tolerance Europe Summit is the first European centric\, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity. \nTo learn more about this event\, and to register online\, visit http://www.as-immunetolerance-eu.com/
URL:https://www.pharmajournalist.com/event/antigen-specific-immune-tolerance-europe-summit/
LOCATION:Park Plaza Victoria\, 239 Vauxhall Bridge Road\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181211
DTEND;VALUE=DATE:20181214
DTSTAMP:20260515T001419
CREATED:20181031T155925Z
LAST-MODIFIED:20181031T160117Z
UID:18205-1544486400-1544745599@www.pharmajournalist.com
SUMMARY:Tumor Targeted Lymphocyte Summit
DESCRIPTION:The Tumor Targeted Lymphocyte Summit is the first\, dedicated meeting that unites the expert community working in TIL and CTL therapies to network\, learn and determine strategies to enhance the efficacy of this adoptive cell therapy in solid tumors. \n \nAs CAR-T fails in the fight to deliver efficacy in solid tumors\, the field is desperately exploring alternative adoptive cell therapies which are strong enough to rise to the challenge. TILs and CTLs have successfully been utilized in melanoma and now with patient demand growing\, TIL-based therapies are fast becoming a more attractive approach to solid tumors. \nSounds interesting? Find out more – get free event brochure here: http://bit.ly/2zgKRSx
URL:https://www.pharmajournalist.com/event/tumor-targeted-lymphocyte-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181212
DTEND;VALUE=DATE:20181214
DTSTAMP:20260515T001419
CREATED:20181005T130934Z
LAST-MODIFIED:20181005T130934Z
UID:17934-1544572800-1544745599@www.pharmajournalist.com
SUMMARY:7th Lung Cancer Screening & Continuum of Care
DESCRIPTION:ACI is excited to announce our 7th Lung Cancer Screening & Continuum of Care Conference on December 12-13\, 2018. A dedicated forum to learn and network with representatives from organizations nationwide that are prepared to deliver superior service in thoracic oncology. \nOur event will be an exploration of techniques and policy changes to better fit lung screening programs through case studies\, research findings and organizational models from renowned healthcare and radiology institutions. The top thoracic oncology programs in the country will showcase their successes and share strategies in achieving excellence in patient care and cost-effective management. \n \nThis two-day event will focus on implementing lung screening programs and services to maximize competitive advantage\, meet increased demand and exceed patient satisfaction. The goal of this event is to bring industry leaders together\, highlight the best practice achievements\, and discuss the current issues and developments in imaging services for the thoracic oncology community. \nLung cancer is the leading cause of cancer-related deaths in the United States. This largely stems from lung cancer’s minimal symptoms in its early stages\, which is when the disease is most treatable. For this reason\, there is a push for regions to offer screening services for their populations\, enabling potential patients to receive care at the most opportune time. Providing this service to potential patients comes with its own challenges\, such as motivating patients to get screened regularly\, generating funding for these services\, raising awareness in your community and many more.
URL:https://www.pharmajournalist.com/event/7th-lung-cancer-screening-continuum-of-care/
LOCATION:Tampa\, FL\, USA\, FL\, United States
ORGANIZER;CN="ACI":MAILTO:rafael@acieu.net
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181212
DTEND;VALUE=DATE:20181214
DTSTAMP:20260515T001419
CREATED:20181025T095842Z
LAST-MODIFIED:20181025T095842Z
UID:18110-1544572800-1544745599@www.pharmajournalist.com
SUMMARY:AI & Big Data for Pharma\, part of DATAx
DESCRIPTION:AI & Big Data for Pharma Summit 2018: Leverage Data Analytics to Deliver Patient-Centric Outcomes \n \nWith the race to adopt data and analytics\, the pharma ecosystem is transforming to keep up with the rapid pace of change. Unprecedented volumes of real-time data are right at our fingertips\, leaders must think strategically about how to gather\, harvest\, and leverage insights. The is the must-attend event to enhance AI and analytics capability in drug discovery and development\, translate patient data into meaningful insights\, and master the art of a seamless journey in pharma supply chain and logistics. \nTopic Areas Covered Include: \n\nLeveraging real time data in R&D and challenges of unstructured data\nAccelerating drug discovery and development through advanced analytics\nStreamlining clinical trial efficiency using AI and machine learning\nCultivating industry partnerships to build knowledge networks\nThe changing face of pharma and how the industry is evolving\nRise of the digital patient: Personalised patient care\, precision medicine and AI\nManaging demand forecasting\, planning\, and reduce waste in commercial analytics\nTransparency in the global supply chain and optimising robotics and AI\n\nFind out more information and register here: http://bit.ly/2O3MQ1Z
URL:https://www.pharmajournalist.com/event/ai-big-data-for-pharma/
LOCATION:New York Hilton Midtown
ORGANIZER;CN="The Innovation Enterprise Ltd.":MAILTO:http://bit.ly/2O3MQ1Z
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181214
DTEND;VALUE=DATE:20181217
DTSTAMP:20260515T001419
CREATED:20171204T015322Z
LAST-MODIFIED:20171204T020748Z
UID:4939-1544745600-1545004799@www.pharmajournalist.com
SUMMARY:Myanmar Phar-Med 2018
DESCRIPTION:This is the biggest trade fair for the medical industry in Myanmar\, focused on hospital\, diagnostic\, pharmaceutical\, medical and rehabilitation sectors\, providing the perfect platform to discover the latest industry innovations\, to network and do business.
URL:https://www.pharmajournalist.com/event/myanmar-phar-med-2018/
LOCATION:Rose Garden Hotel\, Yangon\, Myanmar
ORGANIZER;CN="VEAS Co.%2C Ltd":MAILTO:info@veas.com.vn
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181214
DTEND;VALUE=DATE:20181217
DTSTAMP:20260515T001419
CREATED:20171204T015507Z
LAST-MODIFIED:20171204T020628Z
UID:4943-1544745600-1545004799@www.pharmajournalist.com
SUMMARY:Myanmar Lab Expo 2018
DESCRIPTION:The most definitive event for Laboratory Industry in Myanmar. Gathering the region’s hospital\, Diagnostic\, Laboratory\, Analytical\, Biotechnology and Scientific Instruments & Technology sectors in one convenient location and providing the perfect platform to discover the latest industry innovations\, to network and do business.
URL:https://www.pharmajournalist.com/event/myanmar-lab-expo-2018/
LOCATION:Rose Garden Hotel\, Yangon\, Myanmar
ORGANIZER;CN="VEAS Co.%2C Ltd":MAILTO:info@veas.com.vn
END:VEVENT
END:VCALENDAR